European MPs offer extension of patents to companies developing drugs for childrenBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7517.595-a (Published 15 September 2005) Cite this as: BMJ 2005;331:595
- Rory Watson
European Union legislation designed to encourage pharmaceutical companies to develop drugs specifically tailored to children's needs has moved closer to the statute book after members of the European parliament (MEPs) voted to endorse it.
Françoise Grossetête, the French Christian Democrat member who steered the bill through the parliament, said after the vote: “What concerns me are the 100 million Europeans who are under 18 years of age. Thanks to the European Union, our children will soon benefit from appropriate and safe medicines and will no longer have to depend on the good will of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial